soul trial semaglutide Ongoing #GLP1 -RA Trials on #ASCVD #SELECT: vs Placebo in Patients With Obesity and ASCVD Without DM #SOUL: Semaglutide vs Placebo in Adults With T2D With ASCVD or CKD #SURPASS-CVOT: Tirzepatide Results of SOUL Trial with

Citations Shor, R., et al, "Glucagon-Like Peptide-1 Receptor Agonists and Risk of Neovascular Age-Related Macular Degeneration," JAMA Ophthalmology, June 5, 2025, doi: 10.1001/jamaophthalmol.2025.1455 Edinoff, A.N., et al, "Selective Serotonin Reuptake Inhibitors and Associated Bleeding Risks: A Narrative and Clinical Review," Health Psychology Research, Nov 3, 2022, DOI: 10.52965/001c.39580 Dalton, S.O., et al, "SSRIs and upper gastrointestinal bleeding: what is known and how should it influence prescribing?," CNS Drugs, 2006, DOI: 10.2165/00023210-200620020-00005 Hussain, S., et al, "Proton pump inhibitors' use and risk of hip fracture: a systematic review and meta-analysis," Rheumatology International, Nov

, Borges, N

Over the course of a 42-day study, fat oxidation increased by as much as 62 percent in some subjects

That decision frequently makes things worse, not better

Additionally, STING agonist treatment eliminates these cells in a T and NK cell-dependent manner, offering a promising strategy to prevent metastatic relapse 147